Core Viewpoint - COSCIENS Biopharma Inc. has initiated its Phase 2a clinical efficacy study for its avenanthramides product, aimed at managing inflammation-related conditions, following a successful Phase 1 trial that demonstrated a favorable safety profile [1][4][5]. Group 1: Clinical Study Details - The Phase 1-2a clinical trial, named the AvenActive study, began in November 2023 and involved 72 healthy subjects, with no significant adverse events reported [3][8]. - The Phase 2a study will enroll 20 patients with mild to moderate inflammation, testing doses of 480 mg and 960 mg per day [4][5]. - Initial dosing for the Phase 2a study is expected to occur on March 14, 2025, at the Montreal Heart Institute [4][8]. Group 2: Product Information - Avenanthramides are di-phenolic compounds found in oats, known for their antioxidant and anti-inflammatory properties [2]. - The study will assess inflammatory biomarkers in blood, focusing on cytokines, chemokines, and high-sensitivity C-reactive protein [5]. Group 3: Company Strategy and Market Potential - The successful completion of the Phase 1 study is viewed as a critical milestone, positioning the company for potential out-licensing and commercialization opportunities [6]. - The company aims to become a global leader in natural-based health and wellness products, with avenanthramides seen as a transformative product [6][10].

As filed with the Securities and Exchange Commission on May 13, 2024 Registration No. 333-277115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) K ...

As filed with the Securities and Exchange Commission on April 29, 2024 Registration No. 333-277115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction of incorporation or organization) Canada 2834 Not Applicable (Primary Standard Industria ...

FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. As filed with the Securities and Exchange Commission on February 15, 2024 Registration No. 333-___________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Canada 2 ...